Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Obstetrics and Gynaecology
  • Obstetrics and Gynaecology News
  • Extending letrozole...

Extending letrozole treatment duration effective in inducing ovulation in women with PCOS

Written By : Dr Nirali Kapoor |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-12-29T20:00:42+05:30  |  Updated On 29 Dec 2022 8:01 PM IST
Extending letrozole treatment duration effective in inducing ovulation in women with PCOS
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Polycystic ovary syndrome (PCOS) is a complex reproductiveand metabolic disorder and is the most common cause of anovulatory infertilityin women of reproductive age. Letrozole (LE), a specific aromatase inhibitor,was administered to women with PCOS who were resistant to clomiphene citrate(CC). LE could prevent the hypothalamic– pituitary axis from receiving estrogennegative feedback by inhibiting estrogen biosynthesis, thus increasing folliclestimulating hormone (FSH) production and promoting follicle growth. Recently,LE gradually has replaced CC as the first-line ovulation induction agentadministered to women with PCOS owing to the high rates of live birth andpregnancy.

The commonly used LE regimen for ovulation induction inwomen with PCOS is 2.5 mg daily for 5 days. If the initial dose fails toinitiate follicular development, it often is increased to 5 mg in the nextcycle after a progesterone-induced withdrawal period, and a maximum daily doseof 7.5 mg will be used in the subsequent cycle if still anovulatory.

In accordance with the theory that the ''FSH window'' is asimportant as the ''FSH threshold'' during the selection of dominant follicles,we hypothesized that longer treatment with LE could extend the ''FSH window'',thereby inducing follicle growth in patients who initially do not respond toroutine treatment.

In Xiuxian Zhu and Yonglun Fu's study, considering the riskof ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies, the FSHwindow was widened in a stepwise manner by extending the LE treatment durationstep by step. They defined LE resistance as failure of ovulation after a 5-dayregimen of 5 mg of LE per day for at least 1 cycle. For women with PCOS and LEresistance, a 7-day regimen of 5 mg LE daily was prescribed in the firstovulation induction cycle, and if ovulation did not occur, a 10-day regimen wasprescribed in the subsequent cycle. Such a method of extending LE treatmentduration was named as a ''2-step extended LE regimen'' in the present study.Herein, they reported the ovulation rates and clinical pregnancy outcomes inwomen with PCOS and LE resistance who underwent ovulation induction using the2-step extended LE regimen.

This retrospective study was conducted at Shanghai FirstMaternity and Infant Hospital. Records of women with PCOS and LE resistance whounderwent ovulation induction using the 2-step extended LE regimen betweenOctober 2019 and December 2021 were screened. A total of 69 women with PCOS andLE resistance were included. Ovulation rate was the primary outcome. Clinicalpregnancy rate, live birth rate, spontaneous ovulation rate, and ovarianhyperstimulation syndrome rate were the secondary outcomes. Study resultsdemonstrated that extending LE treatment duration is a feasible method forinducing ovulation in women with PCOS and LE resistance.

Of the 69 patients, 48 ovulated after the 7-day and 16 afterthe 10-day regimen. Overall, the cumulative ovulation rate reached 92.75%(64/69) after the 2-step extended LE regimen, with a cumulative clinicalpregnancy rate of 31.88% (22/69) and a cumulative live birth rate of 24.63%(17/69). All patients ovulated spontaneously without exogenous trigger agentsand none experienced ovarian hyperstimulation syndrome.

Of the 69 women with PCOS and LE resistance, 48 achievedovulation after LE treatment duration was increased to 7 days, among whom 17became pregnant and 14 achieved a live birth.

For the other 21 women, LE treatment duration was increasedto 10 days; among whom 16 achieved adequate follicular growth, 5 becamepregnant, and 3 achieved a live birth.

Overall, the cumulative ovulation rate reached 92.75%, thecumulative CPR was 31.88%, and the cumulative live birth rate was 24.64%. Studyresults demonstrated that extending LE treatment duration is a feasible methodfor inducing ovulation in women with PCOS and LE resistance.

Adding exogenous human chorionic gonadotropin orgonadotropin-releasing hormone agonist when at least 1 follicle has a diameterof >18 mm is a routine procedure in the management of women with ovulatorydysfunction. From authors' perspective, the administration of exogenous triggerdrugs is unnecessary. Because of the short half-life of LE (approximately 45hours), serum E2 values could gradually rise after LE treatment isdiscontinued. Thus, one can just wait for the spontaneous LH surge and thesubsequent rupture of dominant follicles. There are concerns about thepotential risk of ovulation failure of larger follicles, as follicles >22 mmwere related to a higher incidence of unruptured follicles in a previous study.In this study, follicles >25 mm were observed in 11 patients. All of themspontaneously ovulated without the addition of exogenous human chorionic gonadotropinor gonadotropin-releasing hormone.

During the ovulation induction cycle using the 2-stepextended LE regimen, the endometrium was thin at the early follicular phaseowing to the daily administration of LE at a dose of 5 mg, which could decreasethe E2 levels by 97%– 99%. Once circulating E2 levels increased, endometrialdevelopment accelerated. The strategy of waiting for spontaneous ovulationensured that there was sufficient time for patients to achieve adequateendometrial thickness before ovulation. The mean endometrial thickness beforeovulation was 10.58 ± 2.63 mm in the 7-day regimen recipients and 10.8 ±2.74 mm in the 10-day regimen recipients. These values were not less than themean endometrial thickness values in those who underwent a 5-day regimen of LE,2.5 or 5 mg daily. A duration-dependent reduction in the endometrial thicknesswas not observed in study.

In conclusion, study findings demonstrated that extending LEtreatment duration is a feasible method for inducing ovulation in women withPCOS and LE resistance. Whether extending LE duration for a longer time will beeffective in patients who do not respond to a 10-day regimen of 5 mg LE dailyremains our further explorations. Large-scale prospective studies are needed tovalidate our findings and provide evidence for the individual usage of LE inthe ovulation induction of women with PCOS.

Source: XiuxianZhu and Yonglun Fu; Fertility and Sterility

https://doi.org/10.1016/j.fertnstert.2022.09.018


Letrozolepolycystic ovary syndrome
Source : Fertility and Sterility
Dr Nirali Kapoor
Dr Nirali Kapoor

    MBBS, MD Obstetrics and Gynecology

    Dr Nirali Kapoor has completed her MBBS from GMC Jamnagar and MD Obstetrics and Gynecology from AIIMS Rishikesh. She underwent training in trauma/emergency medicine non academic residency in AIIMS Delhi for an year after her MBBS. Post her MD, she has joined in a Multispeciality hospital in Amritsar. She is actively involved in cases concerning fetal medicine, infertility and minimal invasive procedures as well as research activities involved around the fields of interest.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok